HP 0.35, a cephalosporin degradation product is a specific inhibitor of lentiviral RNAses H.
Penicillins, cephalosporins and other betalactam antibiotics are widely used antibacterial drugs. Recently it was found that some of them also have effects on proliferating eukaryotic cells (Neftel, K.A. and Hübscher, U. (1987) Antimicrob. Agents Chemother. 31, 1657-1661), and one such effect was shown to be the inhibition of DNA polymerase alpha (Huynh Do,U., Neftel, K.A., Spadari, S. and Hübscher, U. (1987) Nucl. Acids Res. 15, 10495-10506). The data suggested that degradation products of betalactam antibiotics were responsible for the inhibitory effect on DNA polymerase alpha. There is some confirmation at the structural level, since we found that penicillin binding proteins, the natural target of the cephalosporins, share amino-acid homologies to DNA polymerases and also to reverse transcriptase from HIV1 (Hafkemeyer, P., Neftel, K.A. and Hübscher, U. Meth. Find. Exp. Clin. Pharmacol. 12, 43-46, 1990). We have purified and determined the structure of one product from the cephalosporin Ceftazidim and found one molecule (HP 0.35) that did not interfere with eukaryotic cell proliferation but rather had a specific inhibitory effect on the RNase H activity of human immunodeficiency virus 1 (HIV1) and feline immunodeficiency virus (FIV) reverse transcriptases, while the DNA polymerising activity of these enzymes was not affected. RNases H from HeLa cells, calf thymus and Escherichia coli on the other hand were much less affected by HP 0.35. The inhibitory concentration of 50% (IC50) was more than 10 times lower compared to those of all cellular RNases H. We therefore tested the effect of HP 0.35 on in vitro lentivirus infection as exemplified by FIV-infection of CD(4+)-cat lymphocytes in cell culture. Under conditions where cell proliferation was absolutely unaffected, HP 0.35 was able to inhibit FIV-infection in CD(4+)-cat lymphocytes. Moreover, preincubation of these lymphocytes with HP 0.35 rendered the cells completely unsusceptible to FIV-infection. These data suggest that a degradation product of a clinically used betalactam antibiotic might represent an effective inhibitor class for lentiviral RNase H.
Hafkemeyer
P
P
Department of Pharmacology and Biochemistry, University of Zürich-Irchel, Switzerland.
Neftel
K
K
Hobi
R
R
Pfaltz
A
A
Lutz
H
H
Lüthi
K
K
Focher
F
F
Spadari
S
S
Hübscher
U
U
D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000382:microbiology; D002415:Cats; D002417:Cattle; D002442:Ceftazidime / Q000378:metabolism / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D004722:Endoribonucleases / Q000037:antagonists & inhibitors* / Q000302:isolation & purification; D004926:Escherichia coli / Q000201:enzymology; D015497:HIV-1 / Q000187:drug effects / Q000201:enzymology*; D006367:HeLa Cells / Q000201:enzymology; D006801:Humans; D016089:Immunodeficiency Virus, Feline / Q000187:drug effects / Q000201:enzymology*; D007700:Kinetics; D012194:RNA-Directed DNA Polymerase / Q000302:isolation & purification; D018894:Reverse Transcriptase Inhibitors; D016914:Ribonuclease H; D018139:Simplexvirus / Q000201:enzymology; D013844:Thiazoles / Q000494:pharmacology*; D013950:Thymus Gland / Q000201:enzymology
D018894:Reverse Transcriptase Inhibitors; D013844:Thiazoles; C070329:HP 0.35; D002442:Ceftazidime; D012194:RNA-Directed DNA Polymerase; D004722:Endoribonucleases; D016914:Ribonuclease H